Editing Pioglitazone (section)

===Bladder cancer===
On 9 June 2011, the [[French Agency for the Safety of Health Products]] decided to withdraw pioglitazone due to high risk of [[bladder cancer]].<ref>{{cite web | title = L'antidiabétique Actos retiré du marché | trans-title = Actos antidiabetic withdrawn from the market | language = fr | url = http://www.lefigaro.fr/flash-actu/2011/06/09/97001-20110609FILWWW00505-info-le-figaro-lantidiabetique-actos-retire-du-marche.php | work = Le Figaro | date = 9 June 2011 | access-date = 9 June 2011 | archive-date = 12 June 2011 | archive-url = https://web.archive.org/web/20110612001536/http://www.lefigaro.fr/flash-actu/2011/06/09/97001-20110609FILWWW00505-info-le-figaro-lantidiabetique-actos-retire-du-marche.php | url-status = live }}</ref> This suspension was based on the results of an epidemiological study conducted by the French National Health Insurance. According to the results of the epidemiological study, the French agency found that patients, who were taking Actos for a long time to aid in type 2 diabetes mellitus, significantly increased risk of bladder cancer compared with patients who were taking other diabetes medications.<ref>{{cite web | vauthors = Alam II | date = 1 January 2012 | url = http://www.medical-reference.net/2011/12/france-and-germany-suspended-use-of.html | title = France and Germany Suspended Use of Actos for Bladder Cancer Risk | work = Medical-Reference | access-date = 27 August 2012 | archive-date = 2 September 2012 | archive-url = https://web.archive.org/web/20120902222645/http://www.medical-reference.net/2011/12/france-and-germany-suspended-use-of.html | url-status = live }}</ref> On 10 June 2011, Germany's [[Federal Institute for Drugs and Medical Devices]] also advised doctors not to prescribe the medication until further investigation of the cancer risk had been conducted.<ref>{{cite news | url=https://www.reuters.com/article/takeda-germany-idUSL3E7HA0X920110610 | work=Reuters |  vauthors = Topham J | title=UPDATE 2-Germany joins France in suspending top Takeda drug | date=10 June 2011 | access-date=1 July 2017 | archive-date=13 November 2015 | archive-url=https://web.archive.org/web/20151113074307/http://www.reuters.com/article/2011/06/10/takeda-germany-idUSL3E7HA0X920110610 | url-status=live }}</ref>

On 15 June 2011, the U.S. [[Food and Drug Administration|FDA]] announced that pioglitazone use for more than one year may be associated with an increased risk of bladder cancer, and two months later the label was updated with an additional warning about this risk.<ref>{{cite web | title = FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines | date = 4 August 2011 | url = https://www.fda.gov/Drugs/DrugSafety/ucm266555.htm | publisher = U.S. [[Food and Drug Administration]] (FDA) | access-date = 16 December 2019 | archive-date = 24 April 2019 | archive-url = https://web.archive.org/web/20190424012237/https://www.fda.gov/Drugs/DrugSafety/ucm266555.htm | url-status = dead }}</ref><ref name="FDA safety">{{cite web | title=Update to ongoing safety review of Actos | website=U.S. Food and Drug Administration | date=18 June 2019 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-ongoing-safety-review-actos-pioglitazone-and-increased-risk | access-date=8 November 2020 | archive-date=28 September 2020 | archive-url=https://web.archive.org/web/20200928032722/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-ongoing-safety-review-actos-pioglitazone-and-increased-risk | url-status=dead }}</ref>

A 2017 meta-analysis found no difference in the rates of bladder cancer attributed to pioglitazone.<ref>{{cite journal | vauthors = Filipova E, Uzunova K, Kalinov K, Vekov T | title = Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis | journal = Diabetes Therapy | volume = 8 | issue = 4 | pages = 705–726 | date = August 2017 | pmid = 28623552 | pmc = 5544610 | doi = 10.1007/s13300-017-0273-4 }}</ref>